Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

12

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Histone deacetylase 1

9

Histone deacetylase 2

9

synaptic transmission, GABAergic

9

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

12

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1964

9

1987

3

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Bipolar disorder, manic episodes

9

Epilepsy

9

Migraine

9

Acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle

3

Recurrent or progressive brain tumors

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

12

Preventing

9

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

9

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Burton, B.S.

9

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

13

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

13

FDA UNII

13

PUBCHEM

13

EPA CompTox

12

ECHA (EC/EINECS)

10

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIEPILEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIEPILEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Fatty acid derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

10

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 11 - 13 of 13 results

First page
Previous page
2
Next page disabled
Next page disabled

VALPROATE CALCIUM

56CCK4F86G

Export Data
Search for Structure

Status:

US Approved Rx (2008)

First approved in 1964

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histone deacetylase 2

Histone deacetylase 1

synaptic transmission, GABAergic

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

VALPROATE SODIUM

5VOM6GYJ0D

Export Data
Search for Structure

Status:

US Approved Rx (2008)

First approved in 1964

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histone deacetylase 2

Histone deacetylase 1

synaptic transmission, GABAergic

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

1-(ETHOXYCARBONYLOXY)ETHYL VALPROATE

D9VW6400WJ

Export Data
Search for Structure

Status:

US Approved Rx (2008)

First approved in 1964

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Histone deacetylase 2

Histone deacetylase 1

synaptic transmission, GABAergic

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

Showing 11 - 13 of 13 results

First page
Previous page
2
Next page disabled
Next page disabled

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1